4-(5-(4-CHLOROPHENYL)-3-(TRIFLUOROMETHYL)-1H-PYRAZOL-1-YL)BENZENESULFONAMIDE, 97%, 10mg

3-Bromo-pyrazolo[1,5-a]pyridine, 97.0%, 25g

3-(2-((1R,4aS,5R,8aS)-5,8a-Dimethyl-2-methylene-5-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)decahydronaphthalen-1-yl)ethyl)furan-2(5H)-one, 98%, 10mg

5-Chloro-1,3,3-trimethylspiro[indoline-2,3'-naphtho[2,1-b][1,4]oxazine], 97.0%, 1g

n-(Tert-butyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide, 98+%, 1g

1-Benzyl-4-bromo-piperidine, 95.0%, 100mg

N'-[1-Amino-2-(4-methoxyphenyl)ethylidene]hydrazine carboxylic acid tert-butyl ester, 95.0%, 1g

3-Iodo-4,5-dimethyl-1H-pyrazole, 97%, 250mg

Recipiente de reacción con brida plana cilíndrico, graduado (1) Fondo redondo, DN 100, 160 mm, Altura, 310 mm, 1 Pieza

1-((3-(5-Nitrofuran-2-yl)allylidene)amino)imidazolidine-2,4-dione, 95.0%, 1g

Methyl 3-Amino-5-cyanobenzoate, 98.0%, 1g

Nin-Formyl-D-tryptophan hydrochloride, 99.0%, 25g

cis-2-Methylcyclohexanol>98.0%(GC)5mL